AGOMAB THERAPEUTICS
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
AGOMAB THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
Ghent, Oost-Vlaanderen, Belgium
Country:
Belgium
Website Url:
http://www.agomab.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
236.96 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Apple Mobile Web Clips Icon Google Font API Google Analytics Google Maps WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-10-28 | Origo Biopharma | Origo Biopharma acquired by AgomAb Therapeutics | N/A |
Investors List
Andera Partners
Andera Partners investment in Series C - AgomAb Therapeutics
Redmile Group
Redmile Group investment in Series C - AgomAb Therapeutics
Pfizer
Pfizer investment in Series C - AgomAb Therapeutics
Asabys Partners
Asabys Partners investment in Series C - AgomAb Therapeutics
Fidelity
Fidelity investment in Series C - AgomAb Therapeutics
Dawn Biopharma
Dawn Biopharma investment in Series C - AgomAb Therapeutics
Canaan Partners
Canaan Partners investment in Series C - AgomAb Therapeutics
Pontifax
Pontifax investment in Series C - AgomAb Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - AgomAb Therapeutics
EQT Life Sciences
EQT Life Sciences investment in Series C - AgomAb Therapeutics
Key Employee Changes
Official Site Inspections
http://www.agomab.com Semrush global rank: 5.45 M Semrush visits lastest month: 1.36 K
- Host name: 20.50.64.17
- IP address: 20.50.64.17
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AgomAb Therapeutics"
About Us – Agomab Therapeutics
Agomab – tackling fibrosis through growth factors Agomab is a biotech company developing novel treatments that aim to preserve and restore organ function in fibrotic diseases. By translating a deep expertise in growth factor biology, we …See details»
AgomAb Therapeutics - Crunchbase Company Profile …
AgomAb Therapeutics may be growing as it has recently secured significant funding, with a $100 million investment in its Series C funding round. This capital infusion is intended to advance the company's ALK5 inhibitor through a phase …See details»
Agomab Therapeutics – Restoring Organ Function
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer Antwerp, Belgium, July 11, 2024 Agomab Therapeutics NV (‘Agomab’) today announced that …See details»
Agomab - LinkedIn
Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. …See details»
Agomab Raises $100 Million Series C to Advance Fibrosis-focused …
Ghent, Belgium, October 11, 2023 – Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management …See details»
AgomAb Company Profile 2024: Valuation, Funding & Investors
AgomAb General Information Description. Developer of agonistic antibodies designed to help in the regeneration of damaged tissues. The company's antibodies offer a comprehensive …See details»
AgomAb Company Profile - Office Locations, Competitors, …
AgomAb Therapeutics is a biotherapeutics company developing molecular therapies for the regeneration of damaged tissues. The Company's unique agonistic monoclonal antibody …See details»
AgomAb Therapeutics - Funding, Financials, Valuation & Investors
AgomAb Therapeutics has acquired Origo Biopharma on Oct 28, 2021. Unlock for free . Funding Rounds. Edit Funding Rounds Section. Number of Funding Rounds 5. ... How much funding …See details»
Agomab Therapeutics - EQT Group
Dec 2, 2024 Agomab Therapeutics is a biotechnology company developing therapies that aim to preserve and restore organ function in fibrotic diseasesSee details»
Agomab Acquires Origo Biopharma, Will Develop Fibrosis Therapies
Oct 29, 2021 Agomab Therapeutics and Origo Biopharma are joining forces to develop new therapies for pulmonary fibrosis and other fibrotic conditions. ... a unique opportunity to …See details»
The Pitch Deck AgomAb Used to Raise a $114 Million Series B
Aug 3, 2022 AgomAb said Pfizer would lend its development expertise to the development of the company's lead compound, AGMB-129, which is being developed to treat Crohn's disease. ...See details»
News & Events – Agomab Therapeutics
Nov 18, 2024 Agomab Therapeutics NV (‘Agomab’) today announced the expansion of its team with two key hires: Reginald Brys will join as Head of Research and Maria Nichol will become …See details»
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in …
Jun 6, 2024 Agomab is evaluating AGMB-447 as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF) in a Phase 1 clinical trial (NCT06181370). ANTWERP, Belgium, June 06, 2024- …See details»
Agomab Therapeutics to Acquire Origo Biopharma
For Agomab Therapeutics Tim Knotnerus, CEO E-Mail: [email protected] Media Requests for Agomab Dr. Stephanie May or Dr. Laura Mittmann Trophic Communications …See details»
Agomab Raises $100 Million Series C to Advance Fibrosis-focused ...
Oct 11, 2023 The proceeds will also enable strategic expansion of the organization and fund general corporate purposes. As part of the Series C funding round, Felice Verduyn – van …See details»
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28 th, 2021, combines Spanish …See details»
Agomab Expands Team with Reginald Brys as Head of Research …
Dec 21, 2021 Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP . Ghent, Belgium, December 21, 2021 – ... positions in the research …See details»
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics. “We would like to thank all the parties who have supported the completion of this transaction.” Agomab will integrate the full Origo team as well as its facilities in Touro …See details»